Signe Stensen
Soborg, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial - Authors' reply.
Journal: Lancet (London, England)
Published: March 27, 2026
Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.
Journal: JAMA cardiology
Published: December 23, 2025
Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).
Journal: Diabetes, obesity & metabolism
Published: November 18, 2025
Changes in how people living with obesity perceive weight-related discussions with their healthcare professional: Results from the cross-sectional online ACTION-DK 2022 and 2024 studies.
Journal: Diabetes, obesity & metabolism
Published: July 16, 2025
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
Journal: Lancet (London, England)
Published: May 13, 2025
Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity.
Journal: Journal of the American College of Cardiology
Published: October 18, 2024
The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial.
Journal: European journal of endocrinology
Published: April 11, 2024
Perceptions, behaviours and potential barriers to effective obesity care. Results from the ACTION-DK study.
Journal: Diabetes, obesity & metabolism
Published: January 31, 2023
The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humans.
Journal: European journal of endocrinology
Published: October 19, 2022
Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes.
Journal: Diabetes
Published: January 20, 2022
Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity.
Journal: Diabetes, obesity & metabolism
Published: January 05, 2022
Last Updated: 09/26/2026